{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Cairns EA"],"pubmed_abstract":["<b>Objective:</b> Evidence is accumulating that components of the <i>Cannabis sativa</i> plant may have therapeutic potential in treating psychiatric disorders. Medicinal cannabis (MC) products are legally available for prescription in Australia, primarily through the Therapeutic Goods Administration (TGA) Special Access Scheme B (SAS-B). Here we investigated recent prescribing practices for psychiatric indications under SAS-B by Australian doctors. <b>Methods:</b> The dataset, obtained from the TGA, included information on MC applications made by doctors through the SAS-B process between 1st November 2016 and 30th September 2022 inclusive. Details included the primary conditions treated, patient demographics, prescriber location, product type (e.g., oil, flower or capsule) and the general"],"journal":["Frontiers in pharmacology"],"pagination":["1142680"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10279775"],"repository":["biostudies-literature"],"pubmed_title":["Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing."],"pmcid":["PMC10279775"],"pubmed_authors":["Benson MJ","Macphail SL","Cohen R","Cairns EA","Mohan A","Sachdev PS","Bedoya-Perez MA","McGregor IS"],"additional_accession":[]},"is_claimable":false,"name":"Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing.","description":"<b>Objective:</b> Evidence is accumulating that components of the <i>Cannabis sativa</i> plant may have therapeutic potential in treating psychiatric disorders. Medicinal cannabis (MC) products are legally available for prescription in Australia, primarily through the Therapeutic Goods Administration (TGA) Special Access Scheme B (SAS-B). Here we investigated recent prescribing practices for psychiatric indications under SAS-B by Australian doctors. <b>Methods:</b> The dataset, obtained from the TGA, included information on MC applications made by doctors through the SAS-B process between 1st November 2016 and 30th September 2022 inclusive. Details included the primary conditions treated, patient demographics, prescriber location, product type (e.g., oil, flower or capsule) and the general","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2026-04-07T13:30:17.428Z","creation":"2025-02-19T04:30:34.836Z"},"accession":"S-EPMC10279775","cross_references":{"pubmed":["37346297"],"doi":["10.3389/fphar.2023.1142680"]}}